Directly Observed Weekly Fluoxetine for Major Depressive Disorder Among Hemodialysis Patients: A Single-Arm Feasibility Trial

Kelley M Kauffman, Jacqueline Dolata, Maria Figueroa, Douglas Gunzler, Anne Huml, Julie Pencak, Martha Sajatovic, Ashwini R Sehgal, Kelley M Kauffman, Jacqueline Dolata, Maria Figueroa, Douglas Gunzler, Anne Huml, Julie Pencak, Martha Sajatovic, Ashwini R Sehgal

Abstract

Rationale & objective: Major depressive disorder (MDD) is common among hemodialysis patients, but treatment can add to their pill burden and may be limited by nonadherence. We sought to investigate the value of directly observed, once-weekly fluoxetine dosing in MDD.

Study design: Feasibility trial of adult hemodialysis patients with untreated MDD. The diagnosis of MDD was determined using the Mini International Neuropsychiatric Interview.

Setting & participants: 16 patients at 15 hemodialysis facilities in Northeast Ohio.

Intervention: Patients were initially prescribed 20 mg of fluoxetine once daily for 2 weeks to assess their tolerance. The patients took this daily fluoxetine unobserved at home. They were then transitioned to 90 mg of fluoxetine once weekly for 10 weeks. The patients took this weekly fluoxetine during hemodialysis treatment and were observed by the study staff. The dose was increased to 180 mg once weekly among patients with an inadequate response based on the judgment of the prescribing clinician.

Outcomes: Mini International Neuropsychiatric Interview diagnosis of MDD at the end of the trial and changes in the Patient Health Questionnaire (PHQ-9) scores over 12 weeks.

Results: One patient withdrew from active treatment after 2 daily doses of 20 mg of fluoxetine because of side effects of stomach cramping, vomiting, dizziness, and lightheadedness but completed the baseline and final assessments. The remaining 15 patients received all scheduled weekly fluoxetine doses during the trial. At 12 weeks, 14 of 16 patients (87.5%) no longer met the criteria for MDD (P < 0.001). Among all participants, the mean PHQ-9 scores decreased from 11.3 to 6.6 (P = 0.002).

Limitations: Small sample size, modestly elevated baseline PHQ-9 scores, no comparison group, and short treatment duration.

Conclusions: Directly observed, once-weekly fluoxetine may be an effective and well-tolerated treatment option for hemodialysis patients. Future research should investigate longer-term health outcomes of weekly fluoxetine in this population and explore the feasibility of implementing this depression treatment model in routine clinical practice.

Trial registration: This trial was registered at clinicaltrials.gov as NCT03390933.

Keywords: Depression; directly observed treatment; end-stage renal disease; fluoxetine; hemodialysis.

© 2022 The Authors.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Consolidated Standards of Reporting Trials flowchart. Abbreviation: COVID-19, coronavirus disease 2019.
Figure 2
Figure 2
Individual-level changes in PHQ-9 scores. Abbreviation: PHQ-9, Patient Health Questionnaire.

References

    1. Cohen S.D., Norris L., Acquaviva K., Peterson R.A., Kimmel P.L. Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Clin J Am Soc Nephrol. 2007;2(6):1332–1342.
    1. Hedayati S.S., Bosworth H.B., Kuchibhatla M., Kimmel P.L., Szczech L.A. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int. 2006;69(9):1662–1668.
    1. Watnick S., Wang P.L., Demadura T., Ganzini L. Validation of 2 depression screening tools in dialysis patients. Am J Kidney Dis. 2005;46(5):919–924.
    1. Kimmel P.L., Peterson R.A., Weihs K.L., et al. Behavioral compliance with dialysis prescription in hemodialysis patients. J Am Soc Nephrol. 1995;5(10):1826–1834.
    1. Boulware L.E., Liu Y., Fink N.E., et al. Temporal relation among depression symptoms, cardiovascular disease events, and mortality in end-stage renal disease: contribution of reverse causality. Clin J Am Soc Nephrol. 2006;1(3):496–504.
    1. Cohen S.D., Kimmel P.L. Nutritional status, psychological issues and survival in hemodialysis patients. Contrib Nephrol. 2007;155:1–17.
    1. Kimmel P.L., Peterson R.A., Weihs K.L., et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int. 2000;57(5):2093–2098.
    1. Lacson E., Jr., Bruce L., Li N.C., Mooney A., Maddux F.W. Depressive affect and hospitalization risk in incident hemodialysis patients. Clin J Am Soc Nephrol. 2014;9(10):1713–1719.
    1. Friedli K., Guirguis A., Almond M., et al. Sertraline versus placebo in patients with major depressive disorder undergoing hemodialysis: a randomized, controlled feasibility trial. Clin J Am Soc Nephrol. 2017;12(2):280–286.
    1. Chiu Y.W., Teitelbaum I., Misra M., de Leon E.M., Adzize T., Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089–1096.
    1. Mehrotra R., Cukor D., Unruh M., et al. Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis: a randomized clinical trial. Ann Intern Med. 2019;170(6):369–379.
    1. Taraz M., Khatami M.R., Dashti-Khavidaki S., et al. Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial. Int Immunopharmacol. 2013;17(3):917–923.
    1. Blumenfield M., Levy N.B., Spinowitz B., et al. Fluoxetine in depressed patients on dialysis. Int J Psychiatry Med. 1997;27(1):71–80.
    1. Ilievska-Poposka B., Zakoska M., Mitreski V. Evaluation of the directly observed treatment’s acceptance by tuberculosis patients in the Republic of Macedonia. Open Access Maced J Med Sci. 2018;6(5):896–900.
    1. Belknap R., Holland D., Feng P.J., et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167(10):689–697.
    1. Karumbi J., Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;2015(5)
    1. Ford N., Nachega J.B., Engel M.E., Mills E.J. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet. 2009;374(9707):2064–2071.
    1. Machouf N., Lalonde R.G. Directly observed therapy (DOT): from tuberculosis to HIV. Rev Epidemiol Sante Publique. 2006;54(1):73–89.
    1. Wohl A.R., Garland W.H., Valencia R., et al. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis. 2006;42(11):1619–1627.
    1. Volmink J., Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2003;1(1)
    1. Mitty J.A., Stone V.E., Sands M., Macalino G., Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis. 2002;34(7):984–990.
    1. Miner C.M., Brown E.B., Gonzales J.S., Munir R. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. J Clin Psychiatry. 2002;63(3):232–240.
    1. Norman T.R., Olver J.S. New formulations of existing antidepressants: advantages in the management of depression. CNS Drugs. 2004;18(8):505–520.
    1. Schmidt M.E., Fava M., Robinson J.M., Judge R. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry. 2000;61(11):851–857.
    1. Claxton A., de Klerk E., Parry M., Robinson J.M., Schmidt M.E. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry. 2000;61(12):928–932.
    1. Hedayati S.S., Yalamanchili V., Finkelstein F.O. A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney Int. 2012;81(3):247–255.
    1. Judge R. Patient perspectives on once-weekly fluoxetine. J Clin Psychiatry. 2001;62(suppl 22):53–57.
    1. Nagler E.V., Webster A.C., Vanholder R., Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP) Nephrol Dial Transplant. 2012;27(10):3736–3745.
    1. Prescriber’s Digital Reference LLC. Fluoxetine hydrochloride-drug summary.
    1. Sheehan D.V., Lecrubier Y., Sheehan K.H., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22–57.
    1. Iovieno N., van Nieuwenhuizen A., Clain A., Baer L., Nierenberg A.A. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety. 2011;28(2):137–144.
    1. Gaynes B.N., Warden D., Trivedi M.H., Wisniewski S.R., Fava M., Rush A.J. What did STAR∗D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychol Serv. 2009;60(11):1439–1445.
    1. Warden D., Rush A.J., Trivedi M.H., Fava M., Wisniewski S.R. The STAR∗D project results: a comprehensive review of findings. Curr Psychiatr Rep. 2007;9(6):449–459.
    1. Center Watch Prozac weekly (fluoxetine HCL)
    1. Wagstaff A.J., Goa K.L. Once-weekly fluoxetine. Drugs. 2001;61(15):2221–2228. discussion 2229.
    1. American Psychiatric Association . 5th ed. American Psychiatric Publishing; 2013. Diagnostic and Statistical Manual of Mental Disorders.
    1. Keers R., Aitchison K.J. Gender differences in antidepressant drug response. Int Rev Psychiatry. 2010;22(5):485–500.
    1. Grigoriadis S., Robinson G.E. Gender issues in depression. Ann Clin Psychiatry. 2007;19(4):247–255.
    1. Sagud M., Hotujac L., Mihaljević-Peles A., Jakovljević M. Gender differences in depression. Coll Antropol. 2002;26(1):149–157.
    1. Kornstein S.G. Gender differences in depression: implications for treatment. J Clin Psychiatry. 1997;58(suppl 15):12–18.
    1. Shao Z., Richie W.D., Bailey R.K. Racial and ethnic disparity in major depressive disorder. J Racial Ethn Health Disparities. 2016;3(4):692–705.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit